Skip to content
10-K

Annual Report

Metagenomi Therapeutics, Inc. MGX

0001193125-26-093976

← back to feed
Filed
Mar 5, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 2, 2026 37.62M sh
Shares Diluted FY 2025 · Dec 31, 2025 37.25M sh
Shares Diluted FY 2025 · Dec 31, 2024 33.03M sh
Capex FY 2025 · Dec 31, 2025 $574K
Capex FY 2025 · Dec 31, 2024 $3.11M
Operating Cash Flow FY 2025 · Dec 31, 2025 −$88.89M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$109.07M
Cash And Equivalents FY 2025 · Dec 31, 2025 $41.72M
Cash And Equivalents FY 2025 · Dec 31, 2024 $27.39M
Stockholders Equity FY 2025 · Dec 31, 2025 $158.6M
Stockholders Equity FY 2025 · Dec 31, 2024 $234.86M
Stockholders Equity FY 2025 · Dec 31, 2023 −$135.58M
Current Liabilities FY 2025 · Dec 31, 2025 $22.93M
Current Liabilities FY 2025 · Dec 31, 2024 $37.31M
Total Liabilities FY 2025 · Dec 31, 2025 $62.51M
Total Liabilities FY 2025 · Dec 31, 2024 $89.74M
Current Assets FY 2025 · Dec 31, 2025 $165.54M
Current Assets FY 2025 · Dec 31, 2024 $257.96M
Total Assets FY 2025 · Dec 31, 2025 $221.1M
Total Assets FY 2025 · Dec 31, 2024 $324.6M
Eps Diluted FY 2025 · Dec 31, 2025 −$2.36
Eps Diluted FY 2025 · Dec 31, 2024 −$2.36
Eps Basic FY 2025 · Dec 31, 2025 −$2.36
Eps Basic FY 2025 · Dec 31, 2024 −$2.36
Sga Expense FY 2025 · Dec 31, 2025 $26.79M
Sga Expense FY 2025 · Dec 31, 2024 $32.02M
Rd Expense FY 2025 · Dec 31, 2025 $94.43M
Rd Expense FY 2025 · Dec 31, 2024 $109.18M
Net Income FY 2025 · Dec 31, 2025 −$87.87M
Net Income FY 2025 · Dec 31, 2024 −$78.06M
Operating Income FY 2025 · Dec 31, 2025 −$96.01M
Operating Income FY 2025 · Dec 31, 2024 −$88.9M
Revenue FY 2025 · Dec 31, 2025 $25.21M
Revenue FY 2025 · Dec 31, 2024 $52.3M